The initial public offering of Gaudium IVF and Women Health began trading on Friday with subdued early demand, reflecting a familiar pattern in India’s primary markets where retail participation often precedes institutional interest. By 10:30 am on the first day of bidding, the issue was subscribed 19 percent, according to exchange data available via official subscription filings, with most applications coming from individual investors.

Gaudium IVF is seeking to raise ₹165 crore through a book-built issue that includes a fresh issue of ₹90 crore and an offer for sale (OFS) of ₹75 crore by promoter and founder Dr Manika Khanna. The price band has been set at ₹75–79 per share, positioning the company in the mid-cap healthcare services space. The IPO will remain open for subscription until February 24, with listing expected on February 27 on both the BSE and NSE.

Retail investors accounted for the bulk of early demand. The retail individual investors (RII) portion was subscribed 31 percent, with bids for 22.75 lakh shares against 73.1 lakh shares reserved for the segment. A large share of these bids - about 19.36 lakh shares - were placed at the cut-off price, indicating willingness among retail applicants to accept the final discovered price rather than specify a limit. Price-specific bids accounted for 3.38 lakh shares.

Participation from high-net-worth individuals and other non-institutional investors was comparatively muted. The non-institutional investor (NII) category saw overall subscription of 14 percent. Within this segment, large applications exceeding ₹10 lakh were subscribed only 7 percent, while smaller NII applications between ₹2 lakh and ₹10 lakh reached 29 percent subscription. The disparity suggests cautious positioning among larger capital allocators even within the non-institutional segment.

Most notable was the complete absence of bids from qualified institutional buyers (QIBs) during the initial hours. The QIB portion, reserved for 41.77 lakh shares, had not received any subscription at the time of reporting. Institutional investors often wait until the final day to place bids, but early participation can signal strong confidence in pricing and business fundamentals. The lack of immediate institutional demand therefore points to a wait-and-watch approach rather than outright rejection.

Ahead of the public issue, the company had secured ₹49.5 crore from anchor investors on February 19, with allocations made at the upper end of the price band. Anchor participation typically provides price discovery support and confidence to other investors, though it does not guarantee strong subscription across categories.

Proceeds from the fresh issue are earmarked primarily for expansion of the company’s fertility clinic network through new IVF centres, along with repayment of certain outstanding borrowings. The strategy reflects an attempt to scale operations in a specialised segment of healthcare services that has seen rising demand due to demographic shifts, delayed parenthood trends, and increasing acceptance of assisted reproductive technologies in urban India.

From a broader market perspective, the opening day response highlights a more selective IPO environment in 2026 compared with the high-liquidity phases seen in earlier years. Retail investors continue to chase listing gains, but institutional investors appear more valuation-sensitive, especially in healthcare services where profitability timelines and regulatory considerations can influence long-term returns.

For the healthcare sector, the IPO underscores growing investor interest in niche service providers rather than large pharmaceutical manufacturers. Fertility clinics represent a fragmented market with significant growth potential but also operational complexity, including high capital expenditure, dependence on specialist doctors, and reputation-driven patient acquisition.